Pozen and partner GlaxoSmithKline announced late this evening that the U.S. Food and Drug Administration (FDA) has approved Treximet for the acute treatment of migraine attacks with or without aura in adults. The news was as expected and results in a $20 million milestone from Glaxo ($10 million for approval and $10 million for the launch) to be recorded by Pozen in the second quarter of 2008. This should lead to profitability in the second quarter. We are maintaining our Buy rating and $18 near-term price target on the shares. We are buyers on this positive news. by Zacks invest all way through blog